Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Viking Therapeutics' stock plummeted 34% in premarket trading following the release of Phase 2 trial results for its oral weight-loss drug, VK2735. Despite demonstrating significant efficacy with up to 12.2% weight loss over 13 weeks compared to placebo, the market reacted negatively, mirroring a similar stock decline for Eli Lilly after its comparable oral GLP-1 data. Analysts highlighted a high discontinuation rate of 38% at the highest dose, which, despite 98% of side effects being mild or moderate, likely contributed to investor concerns and the sharp sell-off.

Analysis

Viking Therapeutics' stock experienced a severe 34% premarket decline despite its Phase 2 trial for the oral weight-loss drug VK2735 demonstrating significant efficacy. The trial showed a weight loss of up to 12.2% after 13 weeks, a result comparable to the 1.3% loss in the placebo group. This market reaction is not isolated, as it mirrors a recent 14% drop in Eli Lilly's stock after it announced similar efficacy data for its own oral GLP-1 drug. The primary driver of investor concern appears to be the drug's tolerability profile, highlighted by a high discontinuation rate of 38% in the highest-dose cohort. While 98% of side effects were classified as mild or moderate, this was overshadowed by the dropout rate, which even analysts on the conference call found puzzling. The company's CEO suggested that broad public awareness of GI side effects from GLP-1 therapies may be contributing to higher-than-expected discontinuation, even within the placebo group (18%), indicating a potential class-wide challenge for oral formulations.

Key Decisions for Investors

• Investors should scrutinize the 38% discontinuation rate as a key risk factor, as it suggests potential commercial challenges for VK2735 regarding patient adherence and tolerability, overshadowing the positive efficacy data.
• Given the market's similar negative reaction to Eli Lilly's comparable data, it is crucial to assess Viking's competitive positioning based not just on efficacy but on a superior safety and tolerability profile, which is currently in question.
• Monitor for further clarification from management on the root causes of the high dropout rates, as any data suggesting this can be managed or improved in future trials could represent a significant catalyst, while continued ambiguity reinforces a bearish outlook.